Journal Watch 16/08/2023Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
SELECT trial: Semaglutide reduces the risk of MACE by 20% in adults with overweight or obesityResults from the SELECT cardiovascular outcomes trial has revealed that semaglutide 2.4mg demonstrated a statistically significant and...
EMA reviewing data after reports of suicidal thoughts and thoughts of self-harm after taking GLP-1a The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) is reviewing data on the risk of suicidal...
Novo Nordisk to protect US patients from unlawful sales of non-FDA approved ‘semaglutide medicines’Novo Nordisk is taking multiple actions to protect US patients from the unlawful marketing and sales of non-FDA approved counterfeit and...
NHS England to prescribe semaglutide, potentially expanding access to tens of thousands of peopleNHS doctors in England could soon be allowed to prescribe more people with Wegovy (semaglutide) under a new pilot scheme. It is hoped the...
AOMs help patients manage postsurgical weight recurrenceAnti-obesity medications, including semaglutide (Ozempic and Wegovy), can effectively help patients manage weight regained after...
FDA warns against using compounded semaglutideThe FDA has received adverse event reports after patients used compounded semaglutide for type 2 diabetes and weight loss. Drug...